CS Diagnostics Corp. Submits Patent Application For CS-Protect Hydrogel in the US Market
CS Diagnostics Corp. (OTCQB:CSDX) has submitted a patent application for its CS-Protect Hydrogel technology, marking a significant milestone in its FDA application process. The company has partnered with Paul & Albrecht Patentanwälte, a prestigious German intellectual property law firm, to protect its innovative organ spacer medical device.
CS-Protect Hydrogel stands out for its versatility in treating various pathologies, featuring advanced molecular structure and chemical physical properties. The partnership with Paul & Albrecht, established in 1977, aims to ensure robust international intellectual property protection for CS Diagnostics' innovations.
CS Diagnostics Corp. (OTCQB:CSDX) ha depositato una domanda di brevetto per la sua tecnologia CS-Protect Hydrogel, segnando un importante passo avanti nel percorso verso l'autorizzazione FDA. La società ha avviato una collaborazione con lo stimato studio di proprietà intellettuale tedesco Paul & Albrecht Patentanwälte per tutelare il suo dispositivo medico innovativo come spacer organico.
Il CS-Protect Hydrogel si distingue per la sua versatilità nel trattamento di diverse patologie, grazie a una struttura molecolare avanzata e a caratteristiche chimico-fisiche raffinate. L'accordo con Paul & Albrecht, fondato nel 1977, mira a garantire una solida protezione internazionale della proprietà intellettuale delle innovazioni di CS Diagnostics.
CS Diagnostics Corp. (OTCQB:CSDX) ha presentado una solicitud de patente para su tecnología CS-Protect Hydrogel, marcando un hito relevante en su proceso de solicitud ante la FDA. La compañía se ha asociado con la prestigiosa firma alemana de propiedad intelectual Paul & Albrecht Patentanwälte para proteger su innovador dispositivo médico espaciador de órganos.
CS-Protect Hydrogel destaca por su versatilidad para tratar diversas patologías, gracias a una avanzada estructura molecular y propiedades físico-químicas. La colaboración con Paul & Albrecht, establecida en 1977, pretende asegurar una sólida protección internacional de la propiedad intelectual de las innovaciones de CS Diagnostics.
CS Diagnostics Corp. (OTCQB:CSDX)는 자사의 CS-Protect Hydrogel 기술에 대해 특허 출원을 제출했으며, 이는 FDA 신청 과정에서 중요한 이정표입니다. 회사는 혁신적인 장기 스페이서 의료기기를 보호하기 위해 저명한 독일 지적재산권 법무법인 Paul & Albrecht Patentanwälte와 협력하고 있습니다.
CS-Protect Hydrogel은 다양한 병증 치료에 적용 가능한 다목적성, 고도화된 분자 구조 및 화학물리적 특성으로 차별화됩니다. 1977년에 설립된 Paul & Albrecht와의 파트너십은 CS Diagnostics의 혁신에 대해 강력한 국제 지적재산권 보호를 확보하는 것을 목표로 합니다.
CS Diagnostics Corp. (OTCQB:CSDX) a déposé une demande de brevet pour sa technologie CS-Protect Hydrogel, marquant une étape importante dans son dossier auprès de la FDA. La société s'est associée au prestigieux cabinet allemand de propriété intellectuelle Paul & Albrecht Patentanwälte afin de protéger son dispositif médical innovant servant d'espacement d'organes.
Le CS-Protect Hydrogel se distingue par sa polyvalence dans le traitement de diverses pathologies, grâce à une structure moléculaire avancée et des propriétés physico-chimiques optimisées. Le partenariat avec Paul & Albrecht, fondé en 1977, vise à assurer une solide protection internationale de la propriété intellectuelle des innovations de CS Diagnostics.
CS Diagnostics Corp. (OTCQB:CSDX) hat eine Patentanmeldung für seine CS-Protect Hydrogel-Technologie eingereicht und damit einen wichtigen Meilenstein im FDA-Antragsprozess erreicht. Das Unternehmen arbeitet mit der renommierten deutschen Patentanwaltskanzlei Paul & Albrecht Patentanwälte zusammen, um sein innovatives Organ-Separator-Medizinprodukt zu schützen.
Das CS-Protect Hydrogel zeichnet sich durch seine Vielseitigkeit bei der Behandlung verschiedener Pathologien sowie durch eine fortschrittliche molekulare Struktur und chemisch-physikalische Eigenschaften aus. Die 1977 gegründete Partnerschaft mit Paul & Albrecht soll einen starken internationalen Schutz des geistigen Eigentums von CS Diagnostics sicherstellen.
- Patent application submission advances FDA approval process for CS-Protect Hydrogel
- Partnership with established international IP law firm strengthens intellectual property protection
- CS-Protect Hydrogel demonstrates versatility for multiple medical applications
- FDA approval process still pending with uncertain timeline
- No revenue generation until regulatory approvals are secured
PARTNERING WITH PAUL & ALBRECHT PATENT LAWYERS
CHEYENNE, WYOMING / ACCESS Newswire / September 8, 2025 / CS Diagnostics Corp. (OTCQB:CSDX) is delighted to announce the submission of its CS-Protect Hydrogel patenting process application as a supporting milestone for its application at the U.S. Food and Drug Administration (FDA). The company has partnered with Paul & Albrecht Patentanwälte PartG mbB, a renowned German intellectual property law firm founded in 1977.
Paul & Albrecht Patentanwälte https://paul-albrecht.com/en/ is recognized for its long-standing expertise in patents, trademarks, and design protection. Serving clients across Germany, Europe, the USA, and Asia, the firm delivers innovative, reliable, and cost-effective IP strategies for global corporations.
CS-Protect Hydrogel is an organ spacer medical device that requires registration or approval from the respective governmental authorities, in particular the Food and Drug Administration (FDA) in the USA. CS-Protect Hydrogelis more versatile and can also be used in other pathologies, and is an advanced technology from molecular structure, chemical physical properties and medical applications.
Thomas Fahrhoefer, President of the Board at CS Diagnostics Corp., added:
"This collaboration underscores our commitment to excellence, both in science and in governance. By working with a firm of Paul & Albrecht's reputation, we are ensuring that our innovations are protected to the highest international standards, thereby supporting sustainable growth and shareholder value."
Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented:
"This step marks an important milestone for CS Diagnostics Corp as we bring our innovative hydrogel technology closer to global recognition. With Paul & Albrecht's legal expertise, we are confident that our intellectual property is protected to the highest international standards."
Forward-Looking Statements
This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.
Actual results achieved may vary from the information provided herein because of numerous known and unknown risks, uncertainties, and other factors.
For further information please visit https://csdcorp.us/ or email: media@csdcorp.us
SOURCE: CS Diagnostics Corp.
View the original press release on ACCESS Newswire
FAQ
What is CS Diagnostics' (CSDX) CS-Protect Hydrogel technology?
Who is CS Diagnostics partnering with for the patent application process?
What is the current regulatory status of CS-Protect Hydrogel?
What are the potential applications of CSDX's CS-Protect Hydrogel?
